Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | PCTP | Q9UKL6 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | METAP1 | P53582 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741629 | 0.84 | GHSR (0.59) | GHSRPCTPGAAALDH1A1MAPT | |
| Formic Acid SCHEMBL3636056 | 0.81 | GHSR (0.55) | GHSRPCTPGAAALDH1A1MAPT | |
| SCHEMBL3806369 | 0.78 | HTR2C (0.37) | GHSRPCTPACKR3GAAMETAP2 | |
| SCHEMBL13044670 | 0.76 | HTR2A (0.44) | GAAALDH1A1KDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL3638821 | 0.75 | MEN1 (0.45) | GAAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3743753 | 0.74 | GHSR (0.49) | GHSRPCTPGAAALDH1A1MAPT | |
| SCHEMBL3636820 | 0.73 | TP53 (0.47) | GAAALDH1A1MAPTKDM4E | |
| SCHEMBL3639221 | 0.73 | GHSR (0.55) | GHSRGAAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3639671 | 0.71 | GHSR (0.58) | GHSRGAAALDH1A1MAPT | |
| SCHEMBL3639373 | 0.71 | GHSR (0.76) | GHSRPCTPGAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | claimed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GIPR, GHSR, GLP1R | GHSR 2/4885PCTP 2293/4885ACKR3 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.